首页> 外文期刊>International Journal of Radiation Oncology, Biology, Physics >Older age predicts decreased metastasis and prostate cancer-specific death for men treated with radiation therapy: Meta-analysis of radiation therapy oncology group trials
【24h】

Older age predicts decreased metastasis and prostate cancer-specific death for men treated with radiation therapy: Meta-analysis of radiation therapy oncology group trials

机译:老年预示着接受放射治疗的男性的转移和前列腺癌特异性死亡减少:放射治疗肿瘤学小组试验的荟萃分析

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: The impact of age on prostate cancer (PCa) outcome has been controversial; therefore, we analyzed the effect of age on overall survival (OS), distant metastasis, prostate cancer-specific death (PCSD), and nonprostate cancer death (NPCD) on patients with locally advanced PCa. Methods and Materials: Patients who participated in four Radiation Therapy Oncology Group (RTOG) phase III trials, 8531, 8610, 9202, and 9413, were studied. Cox proportional hazards regression was used for OS analysis, and cumulative events analysis with Fine and Gray's regression was used for analyses of metastasis, PCSD, and NPCD. Results: Median follow-up of 4,128 patients with median age of 70 (range, 43-88 years) was 7.3 years. Most patients had high-risk disease: cT3 to cT4 (54%) and Gleason scores (GS) of 7 (45%) and 8 to 10 (27%). Older age (≤70 vs. >70 years) predicted for decreased OS (10-year rate, 55% vs. 41%, respectively; p < 0.0001) and increased NPCD (10-year rate, 28% vs. 46%, respectively; p < 0.0001) but decreased metastasis (10-year rate, 27% vs. 20%, respectively; p < 0.0001) and PCSD (10-year rate, 18% vs. 14%, respectively; p < 0.0001). To account for competing risks, outcomes were analyzed in 2-year intervals, and age-dependent differences in metastasis and PCSD persisted, even in the earliest time periods. When adjusted for other covariates, an age of >70 years remained associated with decreased OS (hazard ratio [HR], 1.56 [95% confidence interval [CI], 1.43-1.70] p < 0.0001) but with decreased metastasis (HR, 0.72 [95% CI, 0.63-0.83] p < 0.0001) and PCSD (HR, 0.78 [95% CI, 0.66-0.92] p < 0.0001). Finally, the impact of the duration of androgen deprivation therapy as a function of age was evaluated. Conclusions: These data support less aggressive PCa in older men, independent of other clinical features. While the biological underpinning of this finding remains unknown, stratification by age in future trials appears to be warranted.
机译:目的:年龄对前列腺癌(PCa)结局的影响一直存在争议;因此,我们分析了年龄对局部晚期PCa患者的总生存期(OS),远处转移,前列腺癌特异性死亡(PCSD)和非前列腺癌死亡(NPCD)的影响。方法和材料:研究了参与放射治疗肿瘤学组(RTOG)四项III期试验的患者,分别为8531、8610、9202和9413。 Cox比例风险回归用于OS分析,累积事件分析和Fine和Gray回归用于转移,PCSD和NPCD分析。结果:对4128例中位年龄为70岁(范围43-88岁)的患者的中位随访时间为7.3年。大多数患者患有高危疾病:cT3至cT4(54%)和Gleason评分(GS)分别为7(45%)和8至10(27%)。年龄较大(≤70岁,高于70岁)预计会降低OS(10年率,分别为55%和41%; p <0.0001)和NPCD升高(10年率,分别为28%和46%,分别; p <0.0001)但转移减少(10年率,27%vs. 20%; p <0.0001)和PCSD(10年率,18%vs. 14%; p <0.0001)。为了解释竞争风险,每隔2年分析一次结局,即使在最早的时间段内,转移和PCSD的年龄依赖性差异仍然存在。调整其他协变量后,> 70岁仍与OS降低相关(危险比[HR],1.56 [95%置信区间[CI],1.43-1.70] p <0.0001),但转移减少(HR,0.72) [95%CI,0.63-0.83] p <0.0001)和PCSD(HR,0.78 [95%CI,0.66-0.92] p <0.0001)。最后,评估了雄激素剥夺治疗的持续时间对年龄的影响。结论:这些数据支持老年男性的PCa侵略性较低,与其他临床特征无关。尽管这一发现的生物学基础仍然未知,但在未来的试验中按年龄分层似乎是有必要的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号